Dissecting complement blockade for clinic use

Blood. 2015 Jan 29;125(5):742-4. doi: 10.1182/blood-2014-12-616300.


In this issue of Blood, Peffault de Latour et al describe ex vivo measurements of complement activity in paroxysmal nocturnal hemoglobinuria (PNH) patients on eculizumab treatment. This is the first systematic pharmacodynamic (PD) study of eculizumab in PNH patients which shows that CH50 is a promising biomarker of therapeutic complement blockade.

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / pharmacokinetics*
  • Complement C5 / antagonists & inhibitors*
  • Drug Monitoring / methods*
  • Female
  • Hemoglobinuria, Paroxysmal / drug therapy*
  • Humans
  • Immunologic Factors / pharmacokinetics*
  • Male


  • Antibodies, Monoclonal, Humanized
  • Complement C5
  • Immunologic Factors
  • eculizumab